Peapack Gladstone Financial Corp Has $2.02 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Peapack Gladstone Financial Corp raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 26.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,839 shares of the biopharmaceutical company's stock after acquiring an additional 591 shares during the quarter. Peapack Gladstone Financial Corp's holdings in Regeneron Pharmaceuticals were worth $2,021,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of REGN. OFI Invest Asset Management acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $28,000. Rakuten Securities Inc. lifted its stake in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the last quarter. Avalon Trust Co acquired a new position in Regeneron Pharmaceuticals in the fourth quarter worth $36,000. Crowley Wealth Management Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $36,000. Finally, Private Wealth Management Group LLC raised its holdings in shares of Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 39 shares during the period. Institutional investors own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

REGN has been the subject of several research reports. Robert W. Baird decreased their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating for the company in a report on Wednesday, February 5th. TD Cowen reduced their price objective on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research report on Tuesday, February 4th. Canaccord Genuity Group initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective for the company. Piper Sandler cut their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research note on Monday, January 27th. Finally, Bernstein Bank lowered their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $966.88.

Remove Ads

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN traded up $7.79 during trading on Friday, hitting $554.18. The company had a trading volume of 1,170,894 shares, compared to its average volume of 707,716. Regeneron Pharmaceuticals, Inc. has a 52 week low of $525.99 and a 52 week high of $1,211.20. The business's 50-day moving average is $659.94 and its 200 day moving average is $753.23. The company has a market cap of $60.59 billion, a P/E ratio of 14.48, a PEG ratio of 2.34 and a beta of 0.44. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the firm earned $11.86 earnings per share. Regeneron Pharmaceuticals's revenue for the quarter was up 10.3% compared to the same quarter last year. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.